NSG 6005 WEEK 3 LEARNING WORKBOOK
2026 PATIENT ASSESSMENT AND DIAGNOSTIC
REASONING SKILL
◉ Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
3. Induce the metabolism of drugs, such as oral contraceptives,
leading to therapeutic failure
4. Cause nonspecific changes in drug metabolism.
Answer: 3. Induce the metabolism of drugs, such as oral
contraceptives, leading to therapeutic failure
◉ Inhibition of P-glycoprotein by a drug such as quinidine may lead
to:
1. Decreased therapeutic levels of quinidine
,2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination.
Answer: 4. Increased levels of a coadministered drug, such as
digoxin, that requires P-
glycoprotein for absorption and elimination
◉ Warfarin resistance may be seen in patients with VCORC1
mutation, leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
,4. Less risk of drug interactions with warfarin.
Answer: 2. Decreased response to warfarin
◉ Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False.
Answer: 2. False
◉ Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin.
Answer: 3. Cetuximab
, ◉ Carbamazepine has a Black Box Warning recommending testing
for the HLA-
B*1502 allele in patients with Asian ancestry prior to starting
therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in
Asian patients with the HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the
HLA-B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients
with HLA-B*1502 allele
4. Patients who have the HLA-B*1502 allele being more likely to
have a resistance to carbamazepine.
Answer: 3. Increased risk for Stevens-Johnson syndrome in Asian
patients with HLA-B*1502 allele
◉ A genetic variation in how the metabolite of the cancer drug
irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
2026 PATIENT ASSESSMENT AND DIAGNOSTIC
REASONING SKILL
◉ Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
3. Induce the metabolism of drugs, such as oral contraceptives,
leading to therapeutic failure
4. Cause nonspecific changes in drug metabolism.
Answer: 3. Induce the metabolism of drugs, such as oral
contraceptives, leading to therapeutic failure
◉ Inhibition of P-glycoprotein by a drug such as quinidine may lead
to:
1. Decreased therapeutic levels of quinidine
,2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination.
Answer: 4. Increased levels of a coadministered drug, such as
digoxin, that requires P-
glycoprotein for absorption and elimination
◉ Warfarin resistance may be seen in patients with VCORC1
mutation, leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
,4. Less risk of drug interactions with warfarin.
Answer: 2. Decreased response to warfarin
◉ Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False.
Answer: 2. False
◉ Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin.
Answer: 3. Cetuximab
, ◉ Carbamazepine has a Black Box Warning recommending testing
for the HLA-
B*1502 allele in patients with Asian ancestry prior to starting
therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in
Asian patients with the HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the
HLA-B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients
with HLA-B*1502 allele
4. Patients who have the HLA-B*1502 allele being more likely to
have a resistance to carbamazepine.
Answer: 3. Increased risk for Stevens-Johnson syndrome in Asian
patients with HLA-B*1502 allele
◉ A genetic variation in how the metabolite of the cancer drug
irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
